New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

References

• IDF: IDF Diabetes Atlas http://www.diabetesatlas.org/ 2009
   Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Prentki M Nolan CJ Islet beta cell failure in type 2 diabetes J Clin Invest 2006 116 1802 1812 16823478
   PubMed Web of Science ®Google Scholar
• Mitrakou A Ryan C Veneman T Hierarchy of glycemic thresholds for counter regulatory hormone secretion, symptoms, and cerebral dysfunction Am J Physiol 1991 260 E67 E74 1987794
   PubMed Web of Science ®Google Scholar
• Gallwitz B Therapies for the treatment of type 2 diabetes mellitus based on incretin action Minerva Endocrinol 2006 31 133 147 16682937
   PubMedGoogle Scholar
• Creutzfeldt W The incretin concept today Diabetologia 1979 16 75 85 32119
   PubMed Web of Science ®Google Scholar
• Nauck M Stockmann F Ebert R Creutzfeldt W Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 1986 29 46 52 3514343
   PubMed Web of Science ®Google Scholar
• Nauck MA Heimesaat MM Orskov C Holst JJ Ebert R Creutzfeldt W Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 1993 91 301 307 8423228
   PubMed Web of Science ®Google Scholar
• Nauck MA Kleine N Orskov C Holst JJ Willms B Creutzfeldt W Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 1993 36 741 744 8405741
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP Drewe J Goke B Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 Am J Physiol 1999 276 R1541 R1544 10233049
   PubMed Web of Science ®Google Scholar
• Zander M Madsbad S Madsen JL Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 2002 359 824 830 11897280
   PubMed Web of Science ®Google Scholar
• Drucker DJ The biology of incretin hormones Cell Metab 2006 3 153 165 16517403
   PubMed Web of Science ®Google Scholar
• Deacon CF Nauck MA Toft-Nielsen M Pridal L Willms B Holst JJ Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 1995 44 1126 1131 7657039
   PubMed Web of Science ®Google Scholar
• Mentlein R Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides Regul Pept 1999 85 9 24 10588446
   PubMed Web of Science ®Google Scholar
• Garber AJ Sharma MD Update: vildagliptin for the treatment of type 2 diabetes Expert Opin Investig Drugs 2008 17 105 113
   PubMed Web of Science ®Google Scholar
• Karasik A Aschner P Katzeff H Davies MJ Stein PP Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials Curr Med Res Opin 2008 24 489 496 18182122
   PubMed Web of Science ®Google Scholar
• Thornberry NA Gallwitz B Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4) Best Pract Res Clin Endocrinol Metab 2009 23 479 486 19748065
   PubMed Web of Science ®Google Scholar
• Ahren B Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes Expert Opin Emerg Drugs 2008 13 593 607 19046129
   PubMed Web of Science ®Google Scholar
• Magnin DR Robl JA Sulsky RB Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors J Med Chem 2004 47 2587 2598 15115400
   PubMed Web of Science ®Google Scholar
• Augeri DJ Robl JA Betebenner DA Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 2005 48 5025 5037 16033281
   PubMed Web of Science ®Google Scholar
• Gallwitz B Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes IDrugs 2008 11 906 917 19051153
   PubMed Web of Science ®Google Scholar
• Cao K Bonacorsi SJJr Balasubramanian B Carbon-14 labelling of saxagliptin (BMS-477118) J Labelled Compd Radiopharm 2007 50 1224 1229
   Web of Science ®Google Scholar
• Sharma PN Galvin GM Boettger SD US-20060035954: Ammonolysis process for the preparation of intermediates for DPP IV inhibitors US Patent 2006003595 4 2006
   Google Scholar
• Kim YB Kopcho LM Kirby MS Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118) Arch Biochem Biophys 2006 445 9 18 16364232
   PubMed Web of Science ®Google Scholar
• Metzler WJ Yanchunas J Weigelt C Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation Protein Sci 2008 17 240 250 18227430
   PubMed Web of Science ®Google Scholar
• Wang AY Dorso C Kopcho LM Marcinkeviciene J Kirby MS Implications of the prolonged dissociation rate of saxagliptin, a highly potent and selective DPP4 inhibitor, on plasma DPP measurements Diabetes 2008 57 A576 A577
   Web of Science ®Google Scholar
• Fura A Khanna A Vyas V Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections Drug Metab Dispos 2009 37 1164 1171 19251818
   PubMed Web of Science ®Google Scholar
• Deacon CF Holst JJ Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes Adv Ther 2009 26 488 499 19444391
   PubMed Web of Science ®Google Scholar
• Girgis S Patel CG Li L Effect of diltiazem on the pharmacokinetics of saxagliptin in healthy subjects J Clin Pharmacol 2007 47 119
   Web of Science ®Google Scholar
• Boulton DW Brenner E Royzman K Li L Effect of ketoconazole on the pharmacokinetics of saxagliptin in healthy subjects J Clin Pharmacol 2007 47 1203
   Web of Science ®Google Scholar
• Boulton DW Adams D Li L Magnesium and aluminum hydroxides plus simethicone, famotidine, or omeprazole do not meaningfully affect the pharmacokinetics of saxagliptin in healthy subjects Clin Pharmacol Therapeutics 2008 83 Suppl 1 S92 S93
   Google Scholar
• Boulton DW Li L Patel CG No pharmacokinetic interaction between saxagliptin and digoxin in healthy subjects Clin Pharmacol Therapeutics 2008 83 Suppl 1 S93
   Google Scholar
• Tahrani AA Piya MK Barnett AH Saxagliptin: a New DPP-4 inhibitor for the treatment of type 2 diabetes mellitus Adv Ther 2009 26 736
   Web of Science ®Google Scholar
• DeFronzo RA Hissa MN Garber AJ The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone Diabetes Care 2009 32 1649 1655 19478198
   PubMed Web of Science ®Google Scholar
• Dhillon S Weber J Saxagliptin Drugs 2009 69 2103 2114 19791828
   PubMed Web of Science ®Google Scholar
• Rosenstock J Aguilar-Salinas C Klein E Nepal S List J Chen R Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes Curr Med Res Opin 2009 25 2401 2411 19650754
   PubMed Web of Science ®Google Scholar
• Chacra AR Tan GH Apanovitch A Ravichandran S List J Chen R Saxagliptin added to a submaximal dose of sulphonylurea improves glycemic control compared with up titration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial Int J Clin Pract 2009 63 1395 1406 19614786
   PubMed Web of Science ®Google Scholar
• Jadzinsky M Pfutzner A Paz-Pacheco E Xu Z Allen E Chen R Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial Diabetes Obes Metab 2009 11 611 622 19515181
   PubMed Web of Science ®Google Scholar
• Rosenstock J Sankoh S List JF Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes Diabetes Obes Metab 2008 10 376 386 18355324
   PubMed Web of Science ®Google Scholar
• Hollander P Li J Allen E Chen R Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone J Clin Endocrinol Metab 2009 94 4810 4819 19864452
   PubMed Web of Science ®Google Scholar
• Patel C Castaneda L Frevert U Li L Kornhauser DM Boulton DW Single-Dose Pharmacokinetics and Safety of Saxagliptin in Subjects with Hepatic Impairment Compared with Healthy Subjects Diabetes Care 2008 57 Suppl 1 537
   Google Scholar
• Ahren B Schweizer A Dejager S Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes J Clin Endocrinol Metab 2009 94 1236 1243 19174497
   PubMed Web of Science ®Google Scholar
• Wolf R Frederich R Fiedorek F Evaluation of CV Risk in the Saxagliptin Clinical Trials Diabetes 2009 59 Suppl 1 8-LB
   Google Scholar
• Gallwitz B Häring HU Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas Diabetes Obes Metab 2010 12 1 11 19788431
   PubMed Web of Science ®Google Scholar
• Traynor K FDA approves saxagliptin for type 2 diabetes Am J Health Syst Pharm 2009 66 1513
   Web of Science ®Google Scholar